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Levels of iron and iron-related proteins including ferritin are higher in the lung tissue and lavage fluid 
of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy controls. 
Whether more iron in the extracellular milieu of the lung associates with distinct clinical phenotypes 
of COPD, including increased exacerbation susceptibility, is unknown. We measured iron and ferritin 
levels in the bronchoalveolar lavage fluid (BALF) of participants enrolled in the SubPopulations and 
InteRmediate Outcome Measures In COPD (SPIROMICS) bronchoscopy sub-study (n = 195). BALF Iron 
parameters were compared to systemic markers of iron availability and tested for association with 
FEV1 % predicted and exacerbation frequency. Exacerbations were modelled using a zero-inflated 
negative binomial model using age, sex, smoking, and FEV1 % predicted as clinical covariates. BALF 
iron and ferritin were higher in participants with copD and in smokers without copD when compared 
to non-smoker control participants but did not correlate with systemic iron markers. BALF ferritin and 
iron were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin 
and iron conveying a 24% and 2-fold increase in exacerbation risk, respectively. Similar associations 
were not observed with plasma ferritin. increased airway iron levels may be representative of a distinct 
pathobiological phenomenon that results in more frequent COPD exacerbation events, contributing to 
disease progression in these individuals.
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Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and morbidity worldwide, result-
ing in almost 3 million deaths globally in 2016 and the loss of over 47 million potential life-years1. A significant 
portion of this burden of disease presents as exacerbation events, episodic surges of respiratory symptoms accom-
panied by a more rapid decline in lung function and higher mortality2,3. These exacerbations are largely attributed 
to recurrent acute infection, with host factors also playing a fundamental role4. Identifying and understanding 
host susceptibility risk factors that contribute to repeated exacerbations is imperative to understanding and treat-
ing COPD.
Although the overwhelming risk factor in the industrialized world for COPD development is tobacco smok-
ing, genome wide association studies suggest a pathogenic role for abnormal iron homeostasis5. We recently 
demonstrated that a major iron metabolism protein, iron regulatory protein 2 (IRP2), drives lung inflammation 
and injury in a murine model of COPD5,6. In the lung, iron is found in both unbound and protein-bound forms, 
and several of the most abundant proteins in lung tissue and bronchoalveolar lavage fluid (BALF) bind to and 
regulate iron7–9. One such protein is ferritin, an octahedral polymeric shell composed of light chain (FTL) and 
heavy chain (FTH) subunits that stores ferric (Fe3+) iron atoms in a soluble, non-toxic form10. Previous studies 
have demonstrated release of ferritin from iron-loaded alveolar macrophages (AMs) in smokers, and AM fer-
ritin mRNA levels are increased in active smokers and correlate with airflow limitation in COPD patients11,12. 
Furthermore, total levels of non-heme iron and of other iron-binding molecules including lipocalin-2 and lacto-
ferrin, are increased in lung tissue, sputum, BALF, and AMs of COPD patients, relative to non-smokers9,11–21. 
Conversely, there is also ample evidence for iron deficiency in COPD, and anaemia in COPD is associated with 
worse patient outcomes, including mortality22,23. The biological relevance of such observations remains to be 
elucidated; however, these data strongly support a local iron overload signature in the extracellular milieu of the 
lung in COPD that is distinctive to systemic iron handling, which is intriguing as mainstream cigarette smoke 
contains little iron24,25.
Whether overloaded or deficient, abnormal iron stores may have important immunologic and microbiologic 
implications, and could provide insights into COPD pathogenesis and progression26. However, to our knowledge, 
iron parameters have not been examined for association with clinical phenotypes or outcomes (including exac-
erbation frequency) in a large, well-characterized COPD cohort. In this study, we measured BALF ferritin and 
iron levels in participants enrolled in the extensively characterized SubPopulations and InteRmediate Outcome 
Measures In COPD (SPIROMICS) cohort. We demonstrate that BALF ferritin and iron levels, but not systemic 
iron parameters, are associated with clinical measures of disease activity, most importantly exacerbation fre-
quency. These findings support a hypothesis whereby higher BALF iron levels, reflective of iron overload in the 
lung microenvironment, may represent a novel pathobiological endotype in COPD.
Results
Bronchoscopy sub-study participants. SPIROMICS (ClinicalTrials.gov NCT01969344T4) is an on-go-
ing longitudinal multicentre observational study that recruited 2981 subjects, 40 to 80 years of age, including 
never-smokers (≤1 pack-year of tobacco-smoking history), current or former smokers (ever-smokers, ≥20 






(n = 195) P-value*
Age (y) median [IQR] 64 [56–70] 59 [52–67] <0.001
Sex N (%) 0.89
Male 1577 (53.0%) 102 (52.3%)




Current Non-Smoker 1839 (62.7%) 121 (63.4%)
Current Smoker 1093 (37.3%) 70 (36.6%)
GOLD Stage N (%) <0.001
0 924 (31.1%) 86 (44.1%)
1 404 (13.6%) 32 (16.4%)
2 820 (27.6%) 44 (22.6%)
3 433 (14.6%) 8 (4.10%)
4 186 (6.3%) 0 (0%)










969 (33.7%) 39 (20.3%) <0.001
Table 1. Participants enrolled in SPIROMICS and in the SPIROMICS bronchoscopy sub-study. *Kruskal-
Wallis or Chi-square test comparing patients included in the Bronchoscopy substudy to remaining SPIROMICS 
patients. IQR: interquartile range.
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(n = 215) with post-bronchodilator FEV1 > 30% predicted and without an exacerbation in the prior six weeks 
were further enrolled in a bronchoscopy sub-study. The characteristics of participants of the bronchoscopy sub-
study, in relation to the overall SPIROMICS cohort, are shown in Table 1. Compared to the entire SPIROMICS 
cohort, participants who underwent bronchoscopy were younger, had milder disease, and were less likely to have 
had a COPD exacerbation during study follow-up (Table 1). BALF ferritin and iron were measured in 195 out of 
the total 215 recruited participants in the bronchoscopy sub-study. Plasma ferritin was available for 119 of these 
195 participants in the bronchoscopy sub-study, as well as for 1575 participants in the entire SPIROMICS cohort.
BALF iron parameters in SPIROMICS. We first examined relationships between BALF iron param-
eters and COPD status. Relative to never-smokers (median 10.5 ng/mL), BALF ferritin levels were signifi-
cantly increased in smokers without COPD (26.4 ng/mL; p < 0.0001) and in COPD participants (47.3 ng/mL; 
p < 0.0001) (Fig. 1A). Amongst current smokers, BALF ferritin was higher in participants with COPD than 
in those without COPD (median 119.4 vs. 58.2 ng/mL; p = 0.013) (Fig. 1B). To eliminate the possibility that 
increased BALF ferritin occurred as a result of alveolar epithelial damage and transepithelial protein leakage, a 
sensitivity analysis was performed by normalizing BALF ferritin to BALF total protein and revealed similar, if not 
stronger, associations with disease status relative to unnormalized levels (Supplemental Fig. 1A-B). Ferritin has a 
critical role in iron storage, both protecting the cell from the dangers of labile iron and making it available in times 
of increased demand10. In this study, BALF ferritin correlated (r = 0.34; p < 0.0001) with BALF iron, confirming 
the two are interrelated (Fig. 1C). Similar to ferritin, BALF total iron was also significantly increased in smokers 
without COPD (median 150.95 μg/L; p = 0.032) and in participants with COPD (179.1 μg/L; p = 0.0048) relative 
to never-smokers (107.9 μg/L; Fig. 1D). BALF iron in current smokers with COPD was also higher compared to 
those without COPD (196.9 vs. 154.7 μg/L; p = 0.046) (Fig. 1E).
Similar results were also observed in an independent validation cohort (n = 59 BALF samples, Supplemental 
Table 1). In that cohort, BALF ferritin was higher in smokers (median 57.9 ng/mL; p < 0.0001) and participants 
with COPD (77.6 ng/mL; p < 0.0001) compared to healthy non-smoker controls (5.44 ng/mL), and again higher 
in current smokers with COPD relative to those without (median 112.7 vs. 57.9 ng/mL; p = 0.045) (Supplemental 


















































































Figure 1. Bronchoalveolar lavage fluid (BALF) ferritin and iron levels are increased in smokers and participants 
with COPD. (A–E) Ferritin (ng/mL) and iron (mg/L) levels were measured in the BALF of SPIROMICS 
participants [never-smokers (n = 25), ever-smokers (including current and former smokers) without COPD 
(n = 86) and ever-smokers with COPD (n = 84, and n = 83 for ferritin and iron respectively)]. (A,D) Grey dots 
indicate current smokers at the time of baseline visit. (B,E) BALF ferritin and iron levels in current smokers 
without COPD (n = 39) and with COPD (n = 31) in SPIROMICS. (C) BALF ferritin association with BALF 
iron in never-smokers (n = 25, red), ever-smokers without COPD (n = 86, green) and ever-smokers with 
COPD (n = 84, and n = 83 for ferritin and iron respectively, blue) in SPIROMICS. Data (A,B,D,E) are presented 
as median with box indicating upper and lower quartiles, whiskers indicating extrema, and with P values 
calculated by non-parametric Kruskal-Wallis test. Linear associations (C) were tested with Pearson’s correlation 
coefficient.
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BALF iron was higher in smokers (67.8 μg/L; p = 0.031) and participants with COPD (73.9 μg/L; p = 0.0011) 
compared to non-smokers (22.6 μg/L), but did not differ significantly between current smokers with and without 
COPD (p = 0.35) (Supplemental Fig. 2C–E). The above findings demonstrate that individuals with COPD have 
higher levels of ferritin and iron in the lavage fluid lining the lung, an observation that was strengthened by cur-
rent smoking status.
BALF iron parameters and systemic iron status. Circulating ferritin is widely used clinically as a sur-
rogate of systemic and bone marrow iron stores, and is a component of routine anaemia work-up28. Additionally, 
ferritin is well-recognized as an acute phase reactant and is elevated in many chronic inflammatory diseases29–31. 
To evaluate whether increased BALF ferritin and iron were indicative of a global ferritin or iron increase, we next 
compared BALF and plasma ferritin levels in SPIROMICS bronchoscopy sub-study participants. As with BALF 
ferritin, plasma ferritin was significantly increased in smokers without COPD (median 104.5 ng/mL; p = 0.018) 
and in participants with COPD (105.0 ng/mL; p = 0.0051) relative to never-smokers (53.5 ng/mL) (Fig. 2A). 
However, unlike BALF ferritin, plasma ferritin was not higher in current smokers with COPD versus those with-
out (104.0 vs. 89.0 ng/mL; p = 0.82) (Fig. 2B). Plasma ferritin did not associate with BALF ferritin, supporting 
the possible existence of two distinctive compartments for extracellular ferritin, and demonstrating that ele-
vated BALF ferritin may not be merely a result of spillage from elevated plasma ferritin (Fig. 2C). The above 
plasma ferritin findings among bronchoscopy sub-study participants were also consistent with those of the entire 
SPIROMICS cohort (Supplemental Fig. 3A-B).
Figure 2. Plasma ferritin increases in smokers and in COPD but is not associated with BALF ferritin. (A) 
Plasma ferritin (ng/mL) in never-smokers (n = 20), ever-smokers without COPD (n = 44) and ever-smokers 
with COPD (n = 55) in the SPIROMICS bronchoscopy sub-study were measured using a Luminex-based 
multiplex assay system as described62. Grey dots indicate current smokers at the time of baseline visit. (B) 
Plasma ferritin in current smokers without (n = 17) and with COPD (n = 17) in the SPIROMICS bronchoscopy 
sub-study. (C) Association between plasma ferritin and BALF ferritin. (A,B) median, 25th and 75th percentiles, 
and extrema; P values by non-parametric Kruskal-Wallis test. Linear associations (C) were tested with Pearson’s 
correlation coefficient.
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To test our hypothesis that increased BALF iron in COPD is indicative of a local pathogenic process inde-
pendent of systemic iron levels, we investigated associations between BALF iron parameters and systemic iron 
(haemoglobin) and the systemic inflammatory marker C-reactive protein (CRP). BALF ferritin and iron did 
not associate with haemoglobin or CRP, whereas plasma ferritin strongly associated with haemoglobin and 
not CRP in bronchoscopy sub-study participants (Fig. 3A-B), and with both in the overall SPIROMICS cohort 
(Supplemental Fig. 4A-B).
BALF Iron Parameters, COPD Progression, and Exacerbation Risk. Cigarette smoking and COPD 
are associated with an accelerated decline in lung function, most commonly measured by spirometry and repre-
sented as FEV1 % predicted (forced expiratory volume in one second)32,33. In the SPIROMICS cohort, BALF 
  
    
     
     
     
   
































β =  0.77, p = 0.42ˆ β =  0.06, p = 0.47ˆ
β =  0.04, p = 0.32ˆβ =  0.08, p = 0.83ˆ
β =  4.10, p < 0.001ˆ β =  9.14, p = 0.64ˆ
Figure 3. Local lung ferritin and iron levels do not correlate with systemic markers of iron storage or 
inflammation. (A) Haemoglobin (g/dL) and (B) CRP (μg/mL) levels in never-smokers (n = 25,20, red), ever-
smokers without COPD (n = 85,44, blue) and ever-smokers with COPD (n = 83,55, green), as previously 
measured using a Luminex-based multiplex assay system62 and association with BALF ferritin (ng/mL), BALF 
iron (μg/L), and plasma ferritin (ng/mL) were tested with a linear model on the log-transformed markers and 
accounting for batch and site effects. β̂  denotes adjusted increase in log-10 ferritin associated with unit increase 
in log-10 marker.
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ferritin negatively correlated with FEV1 % predicted in models adjusted for age, sex, smoking status and clinical 
site (10-fold increase in BALF ferritin β̂  = −7.3 points; confidence interval [CI] −13.10, −1.5; p = 0.01) (Fig. 4A). 
This was maintained upon removing never-smokers (adjusted β̂  = −7.53 points; CI −14.11, −0.94; p = 0.02) 
(Supplemental Table 2). BALF iron did not significantly correlate with FEV1% predicted (adjusted β̂  = −4.45 
points; CI −16.87,7.97; p = 0.48) (Fig. 4B). Plasma ferritin also did not correlate with FEV1% predicted in 
adjusted models in the bronchoscopy sub-study (β̂  = 2.18 points; CI −6.86,11.22; p = 0.63) (Fig. 4C) or in the 
overall SPIROMICS cohort (Supplemental Fig. 5). BALF ferritin, BALF iron or plasma ferritin were not associ-
ated with quantifiable radiographic measures of COPD such as small airway disease (PRMFSAD) or emphysema 
(PRMEMPH) (Supplemental Fig. 6A-B and Supplemental Table 2).
FEV1 is closely linked to COPD exacerbations. Patients with frequent exacerbations have steeper decline in 
FEV1, especially in those with early COPD, where each individual exacerbation results in a profound loss of lung 
function34–36. In SPIROMICS, participants in the bronchoscopy sub-study had less severe disease compared to the 
overall cohort, and therefore had fewer exacerbations (Table 1). Nevertheless, compared to participants without 
exacerbations during follow-up, those who did have exacerbations had higher levels of BALF ferritin in adjusted 
models (2-fold increase in ferritin β̂ = 1.39 points; CI 1.08, 1.80; p = 0.012). Similarly, compared to participants 
without exacerbations during follow-up, those who had exacerbations had higher levels of BALF iron (adjusted 
β̂ = 1.90 points; CI 1.11, 3.36; p = 0.022). Plasma ferritin did not associate with exacerbation events in adjusted 
models (β̂ = 0.95 points; CI 0.88, 1.02; p = 0.163) (Fig. 5A–C).
When analysed relative to the baseline visit in a zero-inflated negative binomial model, a 2-fold increase in 
BALF ferritin was associated with a 24% increase in the rate of yearly exacerbations (rate ratio [RR] 1.24; CI 1.05, 
1.47; p = 0.010) (Fig. 5D, Supplemental Table 3). Comparable results were observed adjusting for participant 
age, sex and smoking status, with the point estimate not substantially changed (RR 1.23; CI 0.99, 1.53; p = 0.058) 
(Supplemental Table 3). Similar results were found for BALF iron, for which a 2-fold increase was associated 
with a 2-fold increase in the yearly rate of exacerbations (RR 1.97; CI 1.36, 2.85; p < 0.001 and adjusted RR 
Figure 4. Higher BALF ferritin levels are associated with lower lung function. (A–C) Correlation between 
BALF ferritin (ng/mL), BALF iron (mg/L), and plasma ferritin (ng/mL) in never-smokers (n = 25 for BALF 
ferritin and iron, 20 for plasma ferritin, red), ever-smokers without COPD (n = 86 for BALF ferritin and iron, 44 
for plasma ferritin green) and ever-smokers with COPD (n = 84 for BALF ferritin, 83 for BALF iron, 55 for 
plasma ferritin, blue) and post-bronchodilator FEV1% predicted. Linear associations (A–C) were tested, 
adjusting for age, sex, smoking status and study site. β̂  denotes adjusted increase in log-10 ferritin associated 
with unit increase in log-10 marker.
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1.98; CI 1.33, 2.93; p < 0.001) (Fig. 5E, Supplemental Table 3). Notably, plasma ferritin was not associated with 
exacerbation rate in the bronchoscopy sub-study or in the overall cohort (Fig. 5F, Supplemental Table 3). After 
analysing only exacerbations following the bronchoscopy visit, many exacerbation events were lost and the asso-
ciation between exacerbation rate and BALF ferritin was no longer significant (adjusted RR 1.11; CI 0.88–1.40; 
p = 0.401), but a significant association was maintained for BALF iron (adjusted RR 1.81; CI 1.18–2.76; p = 0.006) 
(Supplemental Table 3).
Discussion
In this study, we found that airway iron parameters were significantly higher in the bronchoalveolar lavage fluid 
of individuals with COPD when compared to “healthy” smokers and controls, and that higher levels of BALF 
ferritin and iron associate with a greater risk for COPD exacerbation. These results, contrasting with the absence 
of similar associations with plasma ferritin, support the hypothesis that changes in “local” lung iron homeostasis 
contribute to COPD pathobiology.
The regulation of iron acquisition, utilization, and storage is fundamental to the correct function of lung 
epithelial, endothelial, and immune cells37. Iron is also crucial for the metabolism and growth of native and path-
ogenic microbes, including those associated with recurrent infections in COPD such as Haemophilus influenzae 
and Pseudomonas aeruginosa38,39. During infection, the host deploys a number of defence mechanisms in an 
attempt to sequester free iron away from bacteria, including promoting iron uptake, increasing intracellular iron 
storage capacity, and secreting proteins (e.g. ferritin, lactoferrin, lipocalin-2) to chelate remaining extracellular 
iron40–42. Saturation of these adaptive mechanisms directly (e.g. smoke) or indirectly (genetic susceptibility) may 
result in an excess of iron in the lung microenvironment, which in turn may influence the size and diversity of 
microbial populations that colonize and proliferate there. In support of this, we have also observed increased 
BALF levels of the siderophore lipocalin-2 in smokers and participants with COPD, when compared to control 
subjects in the SPIROMICS cohort (data not shown). Given the fact that infections are the dominant cause of 
COPD exacerbations, it follows that disrupting such a complex iron regulatory system and changing iron availa-
bility could potentially directly affect exacerbation risk in COPD patients. This is highlighted by the strong associ-
ation between BALF iron levels and exacerbation frequency found in this study, without a concurrent association 
with FEV1, suggesting that this iron-mediated process may precede lung function decline in these patients.
In this study, the source of increased BALF iron and ferritin is unknown. Alveolar macrophages are iron- 
and ferritin-rich in smokers and COPD patients, but both lung epithelial and endothelial cells are also potential 
sources. As previously mentioned, mainstream cigarette smoke contains little iron24,25. We hypothesize that iron 
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Figure 5. Higher BALF ferritin and iron levels are associated with increased exacerbation risk. (A,B) BALF 
ferritin (ng/mL) and BALF iron (µg/mL) in participants who had had one or more acute COPD exacerbation 
(n = 49 for ferritin, n = 48 for iron) when compared to participants who did not (n = 146). (C) Plasma ferritin 
levels in participants with (n = 30) versus without (n = 89) exacerbations. (A–C) median, 25th and 75th 
percentiles, extrema; Adjusted P values (age, sex, smoking status and site) (D–F) Predicted exacerbation rate 
per SPIROMICS bronchoscopy sub-study participant over 3–5 years of follow up by BALF ferritin (ng/mL) (D), 
BALF iron (µg/mL) (E) or plasma ferritin (ng/mL) (F) were estimated with a zero-inflated negative binomial 
model for a participant with a median FEV1 % predicted for (D) BALF ferritin (n = 195), (E) BALF iron 
(n = 194), and (F) plasma ferritin (n = 119).
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accumulates as a biological response to continuous smoke exposure. Specifically, smoke exposure leads to altered 
responses to hypoxia, higher erythropoietin (EPO) levels43 and expanded, but inefficient erythropoiesis in the 
bone marrow (unpublished data)44. This may in turn lead to changes in iron uptake and release in macrophages 
globally, including in the lung, to increase iron availability for hemoglobin synthesis45. Alternatively, alveolar 
macrophage iron metabolism is directly dysregulated upon smoke exposure. Alveolar macrophages from COPD 
patients have markedly depressed M1-responses46 and markers47,48 and lower phagocytic ability49. Such deactiva-
tion in the M1-polarization programme is accompanied by an increase in the expression of wound-healing M2 
markers47,48. Iron regulatory responses also differ between macrophage phenotypes where M1-macrophages accu-
mulate iron as part of a bacteriostatic stratagem, whilst the opposite is the case for M2-macrophages, in which 
iron release is favoured50. Changes in alveolar macrophage biology therefore may favor a phenotype of active iron 
release by the macrophage, leading to increased extracellular iron. Similarly, we believe that the increased level 
of BALF ferritin detected in this and other studies is a result of a biological response to smoke exposure. In the 
lung, intracellular ferritin is comprised of light and heavy chain subunits (FTL and FTH, respectively) in equal 
proportions, and has relatively low iron saturation compared to ferritin from other organs such as the liver or 
spleen51. Extracellular ferritin is also a combination of FTL and FTH, which in serum consists predominantly of 
FTL52,53. FTL may be more abundant than FTH in the BALF of healthy subjects54; however, we did not evaluate 
proportions of FTL and FTH in ferritin found in BALF, and most commercial ELISA kits, including those used 
in this study, are unable to discriminate between these subunits. The purpose of ferritin and iron release into the 
alveolar space is unclear and is currently the subject of further investigation. Ferritin can serve as an iron carrier; 
macrophages, in particular, use ferritin to deliver iron to hepatocytes and erythroid progenitors55,56.
Our findings, in particular the discordance between BALF and plasma ferritin with clinical associations, 
extend on previous studies of serum ferritin levels in COPD patients. Serum ferritin is increased in smokers, 
and while some studies showed higher serum ferritin correlated with worse airflow obstruction, in others higher 
serum ferritin and iron correlated with spirometric protection against cigarette smoke57–59. Such findings do not 
inherently contradict our results, as blood and airway ferritin may be indicative of distinct pathologic mecha-
nisms, and the phenomenon of local iron overload we demonstrated does not exclude systemic iron deficiency in 
some COPD patients. Distinguishing between local and systemic iron status is a crucial subject for future inves-
tigation, as treating one anatomic compartment with iron chelation or supplementation may exacerbate disease 
processes in another.
Our study has several important strengths. This is the largest study of iron metabolism in a prospective COPD 
cohort and exploits the fact that SPIROMICS is enriched for spirometrically mild-to-moderate disease, a delib-
erate design feature to discover factors that lead to disease progression. We included an independent validation 
cohort to corroborate some of our findings. To eliminate the possibility that increased BALF ferritin occurred as 
a result of alveolar epithelial damage and transepithelial protein leakage, we normalized BALF ferritin to BALF 
total protein, which strengthened BALF ferritin correlations with disease status.
Our study also has limitations. We determined smoking status by self-report, unverified in this analysis using 
objective measurements such as urine cotinine; we also limited current smoking status to the baseline visit, rec-
ognizing that study participants could have quit smoking between that visit and their bronchoscopy. Subjects 
who agreed to the bronchoscopy sub-study were self-selected and may not be representative of the general COPD 
population. Critically, the bronchoscopy sub-study population is overly represented by never-smokers and 
ever-smokers with preserved lung function and is constrained further by a safety check on adequate FEV1 on 
the date of bronchoscopy. This stringent selective process limits our statistical power, given the limited numbers 
of severe COPD cases and exacerbations. The timing of bronchoscopy, in some cases up to 1 year after the initial 
visit, further curtails the exacerbation event numbers. In addition, we measured BALF ferritin and iron at a single 
time point, and it is not known whether these levels are stable over time in a given patient, or fluctuate, especially 
around the time of an exacerbation or infection. We correlated BALF ferritin with many clinical variables and 
cannot exclude the possibility that iron metabolism is merely an intermediary between these variables and other 
more established predictors such as FEV1% predicted. Furthermore, our models assume equal follow-up time 
for study participants, whereas in reality that follow-up time varied substantially. Despite these limitations, we 
consider the over-representation of never-smokers and ever-smokers with preserved lung function a strength, in 
that this allowed us to test our hypothesis at an early disease stage, before significant lung function loss has taken 
place. Our study is also the first to associate BALF iron parameters with important COPD outcomes such as exac-
erbation risk, associations that do not exist with plasma ferritin. The lack of associations with radiographic meas-
ures of small airways disease and emphysema further support our hypothesis that higher iron may be associated 
with early disease and may be a factor in COPD pathogenesis. Given the impracticality of routine bronchoscopy 
outside the research setting, our goal is not to advocate for BALF ferritin or iron levels as COPD biomarkers, nor 
to suggest predictive or causal relationships. Instead, we highlight these associations to provide evidence for a 
role for abnormal airway iron metabolism in COPD pathogenesis and progression, to support exploration of the 
basic mechanisms behind this phenomenon as well as to draw attention to the potential of targeting lung iron 
overload in COPD.
In conclusion, BALF ferritin and iron levels are higher in subjects with COPD, an observation that correlates 
with heightened COPD exacerbation susceptibility. If replicated, these results suggest that iron overload might 
represent an under-recognized disease endotype. The pathobiologic mechanism behind these associations war-
rants further investigation.
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Methods
ethics statement. All clinical investigations are conducted according to the principles of the Declaration of 
Helsinki. The individual institutional review boards (IRBs) of all participating clinical centres approved all study 
protocols. All participants understood the purpose of the study and provided written informed consent before 
they underwent any research activities or procedures.
Study design and sample collection. SPIROMICS (ClinicalTrials.gov NCT01969344T4) is an ongo-
ing longitudinal multicenter observational study funded by the National Heart, Lung, and Blood Institute27 that 
recruited 2981 subjects, 40 to 80 years of age, including some who had never smoked cigarettes (≤1 pack-year 
of tobacco-smoking history), current or former smokers (ever-smokers, greater than 20 pack-years) without 
airflow obstruction, and ever-smokers with airflow obstruction60. Data was collected at the initial study visit, 
including demographics, comorbidities, questionnaires, current cigarette smoke exposure and 6-minute walk 
distance (6MWD)27. The extent of airway-wall abnormality was characterized with HRCT scans of the lung, using 
Imbio (parametric response mapping, PRM) and VIDA Diagnostics software; small airway disease (PRMFSAD) 
was defined as areas of lung that are greater than −950 HU on inspiration but less than −856 HU on expiration, 
denoting air-trapping, while emphysema was defined as areas of lung that less than −950 HU on inspiration and 
less than −856 HU on expiration61.
Clinical data was collected at the baseline study visit and in follow-up visits as previously described27. 
Peripheral blood was collected as part of the baseline visit, and plasma biomarkers were measured using a 
Luminex-based multiplex assay; relevant to this study, plasma ferritin was shown to be equivalent to serum fer-
ritin using this assay method62. Exacerbations were defined as health care utilization events (office visit, hospital 
admission, or emergency department visit for a respiratory flare-up) that were treated with antibiotics, systemic 
corticosteroids, or both. Exacerbation history was prospectively collected every 3 months for up to 5 years using 
a structured questionnaire2,60.
A subgroup of subjects (n = 215) with post-bronchodilator FEV1 > 30% predicted and without an exacer-
bation in the prior six weeks were further enrolled in the bronchoscopy sub-study, in which on the first of two 
visits, sputum induction was performed as previously described63. On the second visit, post-bronchodilator FEV1 
was measured and only subjects with an FEV1 > 30% predicted were allowed to participate in the bronchoscopy 
portion of the study. BAL was performed in the right middle lobe and lingula by instilling two aliquots of 40 mL 
and one aliquot of 50 mL per lobe (260 mL total volume), after excluding an initial airway wash sample. Unfiltered 
BALF fluid was collected into a sterilized beaker or in multiple 50 mL conical tubes on ice, then centrifuged at 
300 x g for 5 min and the supernatant aliquoted into 1 mL aliquots for storage at −80 °C, representing one BALF 
sample per patient as described previously63,64. Because no research plasma samples were obtained in the bron-
choscopy sub-study, the plasma biomarkers, including ferritin, in this analysis were measured from the baseline 
visit samples. For participants in the bronchoscopy sub-study, exacerbation events were analysed both relative to 
the baseline visit and to the bronchoscopy visit (0-14 months after baseline visit).
To replicate the study findings in an independent cohort, never smokers (n = 20), healthy smokers (n = 21) 
with normal lung function and individuals with COPD (n = 18), recruited by the Department of Genetic 
Medicine, Weill Cornell Medical College underwent bronchoscopy with BALF isolated as described above (see 
Supplementary Information and Supplemental Table 1).
ferritin measurement and normalization. BALF ferritin was quantified by ELISA using the Abcam 
Human Ferritin ELISA Kit (Cat#ab200018), which detects both ferritin heavy and light chain. BALF ferritin was 
normalized to total protein, measured using the Thermo Scientific Pierce BCA Protein Assay Kit (Cat#23225).
total iron measurements. After centrifugation (1000 × g for 5 mins), 60 μL of BALF was digested with 
40 μL of 50% Nitric Acid (in distilled H2O) containing a final concentration of 0.1% digitonin for 2 hours at 60 °C. 
Total iron, including both bound and unbound forms, was measured in triplicate in 20 μL of digested fractions 
using a graphite furnace atomic absorption spectrophotometer (GFAAS, Perkin Elmer PinAAcle 900z), compar-
ing unknown values to a standard curve of known concentrations of iron (1000 PPM in 2% Nitric Acid).
Statistical analysis. Clinical characteristics of SPIROMICS participants enrolled in the bronchoscopy 
sub-study were compared to those of all SPIROMICS participants, summarized using means and standard devia-
tions or counts and percentages as appropriate. BALF Ferritin and iron were analysed on the log 10 scale. Plasma 
ferritin, haemoglobin and CRP were measured as previously described62, and analysed on the log scale, account-
ing for site and batch effects. Associations between BALF ferritin and baseline characteristics were performed 
using Kruskal-Wallis tests for categorical variables, and Pearson correlations for continuous variables, and were 
unadjusted unless otherwise specified. Sensitivity analyses including all SPIROMICS participants were also per-
formed to study associations in the overall cohort. COPD exacerbations were analyzed in three ways. First, par-
ticipants were dichotomized into those with any exacerbations between their baseline visit and the end of study 
follow-up versus those without exacerbations in this timeframe, and ferritin levels were compared across groups. 
Second, participants were dichotomized into those with any exacerbations between the bronchoscopy visit and 
the end of the study follow-up, versus those without, and ferritin levels were compared across groups. Third, the 
rate of exacerbations per participant per year was estimated using a negative binomial zero-inflated model, with 
% FEV1 predicted as the predictor in the binomial model. Ferritin associations were studied in models unadjusted 
as well as adjusted for age, sex, and smoking status at baseline or at the time of the bronchoscopy, as appropriate. 
Adjustment for study site prevented model convergence and was thus removed. Yearly exacerbation rate ratios, 
as well as 95% confidence intervals (CI) were estimated, and the unadjusted model was then used to plot pre-
dicted exacerbation rates in three years in a participant with a median FEV1% predicted. BALF ferritin levels in 
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a validation cohort (see Supplemental Table 1) were similarly analysed on a log 10 scale, and compared across 
non-smokers, smokers without COPD, and participants with COPD.
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